Heather R. Williams, MD

Heather R. Williams, MD, discusses the evolution of the ovarian cancer treatment paradigm over the past several decades, as well as the importance of continuing to investigate individualized treatment approaches in this population to expand therapeutic options after disease recurrence.

Heather R. Williams, MD, discusses the mechanism of action of antibody-drug conjugates and ADC targets under investigation in patients with ovarian cancer.

Heather R. Williams, MD, discusses ocular toxicities associated with antibody-drug conjugates and strategies for managing these toxicities in patients with ovarian cancer.

Heather R. Williams, MD, discusses the importance of further exploring the use of antibody drug conjugates in ovarian cancer, specifically highlighting the investigation of mirvetuximab soravtansine in this population.

Heather R. Williams, MD, discusses findings from the phase 3 PRIMA trial in patients with ovarian cancer.